MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alcobra Ltd Company Profile (NASDAQ:ADHD)

Consensus Ratings for Alcobra Ltd (NASDAQ:ADHD) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $11.80 (180.29% upside)

Analysts' Ratings History for Alcobra Ltd (NASDAQ:ADHD)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Roth CapitalReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Canaccord GenuityInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Cantor FitzgeraldInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016Jefferies GroupInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016OppenheimerInitiated CoverageOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/9/2015WBB SecuritiesReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Piper JaffraySet Price TargetBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2014FBR & Co.DowngradeOutperform -> Market Perform$22.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Alcobra Ltd (NASDAQ:ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2015Q315($0.31)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015($0.31)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2014Q3 14($0.56)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q2($0.57)($0.57)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Alcobra Ltd (NASDAQ:ADHD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.19)($0.15)($0.17)
Q2 20163($0.22)($0.20)($0.21)
Q3 20163($0.27)($0.22)($0.25)
Q4 20163($0.40)($0.28)($0.32)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)
Dividend History for Alcobra Ltd (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alcobra Ltd (NASDAQ:ADHD)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Alcobra Ltd (NASDAQ:ADHD)
DateHeadline
06/28/16 07:30 AMRoth Capital Reinstates Alcobra Ltd to Buy - Trade Calls
06/28/16 07:30 AMStrong Sell Calls Recommendations For Alcobra Ltd. (NASDAQ:ADHD) At 0 - Investor Newswire
06/27/16 07:04 AMAlcobra Ltd. (ADHD) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 02:16 PMAlcobra Ltd. (ADHD) Updated Price Targets - FTSE News
06/23/16 10:04 AMAlcobra Ltd. (NasdaqGM:ADHD) Stock Momentum Hits Weakness - CML News
06/21/16 07:05 AMStrong Buy Calls Count For Alcobra Ltd. (NASDAQ:ADHD) At 4 - Investor Newswire
06/08/16 08:24 PMAnalysts Offer Insights on Healthcare Companies: Alcobra Ltd (NASDAQ: ADHD), Atara Biotherapeutics Inc (NASDAQ ... - Analyst Ratings
06/07/16 10:42 AMAlcobra Shares Initiated At Buy; Cantor Sees 'Greater Opportunity For Success'
06/07/16 08:41 AMCoverage initiated on Alcobra Pharma by Cantor Fitzgerald -
06/06/16 01:31 PMAlcobra Ltd. :ADHD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 10:11 AMNext Weeks Broker Price Targets For Alcobra Ltd. (ADHD) - Share Trading News
06/03/16 02:20 PMBuy, Sell Or Hold Rating For Alcobra Ltd. (ADHD)? - Share Trading News
06/01/16 10:42 AMAlcobra Ltd. to Participate in Upcoming Investment Conferences - GlobeNewswire (press release) - Alcobra Ltd. to Participate in Upcoming Investment ConferencesGlobeNewswire (press release)TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity ...Alcobra Ltd. (ADHD) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsAlcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Increased By 5.92%HNNall 3 news articles »
06/01/16 07:23 AMAlcobra Ltd. to Participate in Upcoming Investment Conferences - [at noodls] - TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, ...
05/25/16 05:43 PMWere Analysts Bearish Alcobra Ltd (NASDAQ:ADHD) This Week? - Wall Street Hints and News - Were Analysts Bearish Alcobra Ltd (NASDAQ:ADHD) This Week?Wall Street Hints and NewsOut of 6 analysts covering Alcobra (NASDAQ:ADHD), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alcobra has been the topic of 6 analyst reports since August 9, 2015 according to StockzIntelligence Inc. Below is a list of ...and more »
05/22/16 10:26 AMRevenue Update on Alcobra Ltd(NASDAQ:ADHD) - Trade Calls - Revenue Update on Alcobra Ltd(NASDAQ:ADHD)Trade CallsAlcobra Ltd(NASDAQ:ADHD) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 16, 2016. Earnings per share were $-0.18. Analysts had estimated an EPS of $-0.22. In a different note, Jefferies said it ...
05/20/16 09:25 AMAlcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session - Nasdaq - Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in SessionNasdaqAlcobra LtdADHD was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company since ...and more »
05/20/16 07:30 AMAlcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session -
05/20/16 05:08 AM7 Stocks Under $10 Making Big Moves Higher -
05/17/16 05:36 PMAlcobra (ADHD) Gains With Losses on Horizon - Alcobra Ltd (NASDAQ: ADHD) shares advanced 3.7% to $4.18. The company is projected to post a quarterly loss at $0.22 per share. Share volume was 22,000, compared to an all-day average of 27,000
05/16/16 05:30 PMAfter Last Week What Do Analysts Think Of Alcobra Ltd. (ADHD) - Share Trading News - After Last Week What Do Analysts Think Of Alcobra Ltd. (ADHD)Share Trading News12/04/2013 – Stifel Nicolaus began new coverage on Alcobra Ltd. giving the company a “buy” rating. They now have a USD 27 price target on the stock. The share price of Alcobra Ltd. (ADHD) was up +9.81% during the last trading session, with a day high ...Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate UpdateGlobeNewswire (press release)Alcobra's (ADHD) CEO Yaron Daniely on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 6 news articles »
05/16/16 09:49 AMEdited Transcript of ADHD earnings conference call or presentation 16-May-16 12:30pm GMT -
05/16/16 08:30 AMThe Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics -
05/16/16 07:32 AMAlcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, May 16, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused ...
05/16/16 07:15 AMAlcobra reports 1Q loss -
05/16/16 07:03 AM8:03 am Alcobra Pharma reports Q1 results; MEASURE study data expected by year end -
05/16/16 06:07 AMQ1 2016 Alcobra Ltd Earnings Release - Before Market Open -
05/12/16 06:08 PMLatest Analyst Ratings For Alcobra Ltd. (ADHD) - Share Trading News - Latest Analyst Ratings For Alcobra Ltd. (ADHD)Share Trading News02/04/2016 – Alcobra Ltd. had its “buy” rating reiterated by analysts at Roth Capital. 01/25/2016 – Oppenheimer began new coverage on Alcobra Ltd. giving the company a “outperform” rating. They now have a USD 16 price target on the stock. 06/24/2015 ...and more »
05/09/16 04:28 AMAlcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Decreased By 6.4% - B.O.D.Y Confidential - Alcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Decreased By 6.4%B.O.D.Y ConfidentialThe stock of Alcobra Limited Ord (NASDAQ:ADHD) registered a decrease of 6.4% in short interest. ADHD's total short interest was 1.87 million shares in May as published by FINRA. Its down 6.4% from 2.00 million shares, reported previously. With 160,800 ...and more »
05/08/16 06:16 PMBroker Outlook For The Week Ahead Alcobra Ltd. (ADHD) - Share Trading News - Broker Outlook For The Week Ahead Alcobra Ltd. (ADHD)Share Trading NewsAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in ...and more »
05/04/16 06:00 PMBroker Roundup For Alcobra Ltd. (ADHD) - Share Trading News - Broker Roundup For Alcobra Ltd. (ADHD)Share Trading News12/04/2013 – Stifel Nicolaus began new coverage on Alcobra Ltd. giving the company a “buy” rating. They now have a USD 27 price target on the stock. The share price of Alcobra Ltd. (ADHD) was up +2.95% during the last trading session, with a day high ...Alcobra Ltd.: Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call ...The Wall Street Transcriptall 2 news articles »
05/04/16 07:20 AMAlcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16 - [at noodls] - TEL AVIV, Israel, May 04, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, ...
05/03/16 04:40 AMEarnings Per Share for Alcobra Ltd (ADHD) to Decline - B.O.D.Y Confidential - Earnings Per Share for Alcobra Ltd (ADHD) to DeclineB.O.D.Y ConfidentialWall Street await Alcobra Ltd (NASDAQ:ADHD) to release earnings on May, 4. Analysts forecast EPS of $-0.22, up exactly $0.04 or 15.38% from 2014's $-0.26 EPS. After posting $-0.20 EPS for the previous quarter, Alcobra Ltd's analysts now forecast 10.00% ...
04/26/16 06:22 PMStock Falling out of the Sky: Alcobra Ltd. (NASDAQ:ADHD) - The Post - Stock Falling out of the Sky: Alcobra Ltd. (NASDAQ:ADHD)The PostAlcobra Ltd. (NASDAQ:ADHD) was a top loser in today's session as the company saw shares drop -6.44% on the day at the time of writing. Stocks whose market prices drop the most during the trading day are bluntly referred to as losers. Stocks that lose ...
04/22/16 04:45 AMAnalyst Coverage: Alcobra Ltd. (ADHD) - Risers & Fallers - Analyst Coverage: Alcobra Ltd. (ADHD)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Alcobra Ltd. (ADHD). The latest broker reports which are currently outstanding on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
04/20/16 06:19 PMAlcobra Ltd. (NASDAQ:ADHD) Has An Average Rating Of 3.75 - Investor Newswire - Alcobra Ltd. (NASDAQ:ADHD) Has An Average Rating Of 3.75Investor NewswireAlpha One uses algorithm-based analytics to know about a stock sentiment varying as per the published content on online channels. In this analysis, the group considers only the most relevant news sources on a daily basis. Alcobra Ltd. (NASDAQ:ADHD) has ...and more »
04/15/16 07:39 AMAlcobra Limited Ord (NASDAQ:ADHD) Short Interest Decreased By 1.49% - Business Standard Tribune - Alcobra Limited Ord (NASDAQ:ADHD) Short Interest Decreased By 1.49%Business Standard TribuneThe stock of Alcobra Limited Ord (NASDAQ:ADHD) registered a decrease of 1.49% in short interest. ADHD's total short interest was 2.00 million shares in April as published by FINRA. Its down 1.49% from 2.03M shares, reported previously. With 140,200 ...
04/14/16 11:33 PMAlcobra Ltd. (ADHD) Analyst Review - Risers & Fallers - Alcobra Ltd. (ADHD) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Alcobra Ltd. (ADHD). According to the latest broker reports outstanding on Tuesday 12th of April, 3 analysts have a rating of “strong buy”, 2 analysts “buy”, 0 ...
04/13/16 06:17 PMMEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session - MEI Pharma currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%. A better-ranked stock in the same industry is Alcobra Ltd. (ADHD - Snapshot Report), sporting a Zacks Rank #1 (Strong Buy). Is MEIP going up? Or down? Predict to see what ...
04/13/16 09:28 AMAttention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2016; New Report Launched - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, Therapeutics Development, Drug Profiles, Appendix, Methodology. The report covered companies few are - Alcobra Ltd, Amarantus Bioscience Holdings, Inc., APeT ...
04/11/16 06:10 PMShares in Focus - Alcobra Ltd. (NASDAQ:ADHD) - Stock Caller - Shares in Focus - Alcobra Ltd. (NASDAQ:ADHD)Stock CallerAlcobra Ltd. (NASDAQ:ADHD) shares have been given a top rating from Beta Systems research. This rating considers fundamentals, potential future earnings growth and analyst opinions. This data also uses analyst target price and EPS predictions. Traders ...and more »
04/11/16 09:54 AMLatest Analyst Reports On Alcobra Ltd. - Risers & Fallers - Latest Analyst Reports On Alcobra Ltd.Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Alcobra Ltd. (ADHD). The latest broker reports which have been released state 3 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 analysts ...Alcobra Limited Ord (NASDAQ:ADHD) Sellers Covered 3.3% of Their ShortsRiversideGazette.comall 2 news articles »
04/10/16 10:47 AMAre Analysts Bearish Alcobra Ltd (NASDAQ:ADHD) After Last Week? - Clinton Financial - Are Analysts Bearish Alcobra Ltd (NASDAQ:ADHD) After Last Week?Clinton FinancialOut of 6 analysts covering Alcobra (NASDAQ:ADHD), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alcobra was the topic in 6 analyst reports since August 9, 2015 according to StockzIntelligence Inc. Below is a list of Alcobra ...Alcobra Ltd (NASDAQ:ADHD) Receives $12.13 Consensus Price Target from BrokeragesWeb Breaking Newsall 2 news articles »
04/06/16 06:23 PMAlcobra Ltd. (NASDAQ:ADHD): Earnings In Focus - Investor Newswire - Alcobra Ltd. (NASDAQ:ADHD): Earnings In FocusInvestor NewswireFollowing the recent poll, Alcobra Ltd. (NASDAQ:ADHD) can post EPS of $-0.15 in the upcoming results, which can be disclosed anytime around 2016-05-04. The earnings target released by Thomson Reuter's may vary from EPS target of Zacks because both ...and more »
02/19/16 07:15 AMArQule (ARQL) Shows Strength: Stock Adds 7.6% in Session -
02/18/16 07:37 AMHow Alcobra (ADHD) Stock Stands Out in a Strong Industry -
02/17/16 03:49 PMEdited Transcript of ADHD earnings conference call or presentation 17-Feb-16 1:30pm GMT -
02/17/16 07:48 AMCORRECTING and REPLACING -- Alcobra Announces Fourth Quarter and Fiscal 2015 Financial Results and Provides Corporate Update - [GlobeNewswire] - Conference Call& Webcast February 17th at 8:30 a.m. Eastern Time/5: 30 a.m. Pacific Time TEL AVIV, Israel, Feb. 17, 2016-- In a release issued under the same headline earlier today by Alcobra Ltd., please ...
02/17/16 07:15 AMAlcobra reports 4Q loss -
02/17/16 07:00 AMAlcobra Announces Fourth Quarter and Fiscal 2015 Financial Results and Provides Corporate Update - [GlobeNewswire] - Conference Call& Webcast February 17th at 8:30 a.m. Eastern Time/5: 30 a.m. Pacific Time TEL AVIV, Israel, Feb. 17, 2016-- Alcobra Ltd., an emerging pharmaceutical company focused on the development of ...
About Alcobra Ltd

Alcobra Ltd logoAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADHD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.21
  • 50 Day Moving Average: $4.67
  • 200 Day Moving Average: $4.79
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $116.31M
  • Current Quarter EPS Consensus Estimate: $-0.98 EPS
Additional Links:
Alcobra Ltd (NASDAQ:ADHD) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha